The products of arachidonic acid metabolism are key mediators of inflammatory responses in the central nervous system, and yet we do not know the mechanisms of their regulation. The phospholipase A 2 enzymes are sources of cellular arachidonic acid and the enzymes cyclooxygenase-2 (COX-2) and microsomal prostaglandin E synthase-1 (mPGES-1) are essential for the synthesis of inflammatory PGE 2 in the brain. These studies seek to determine the function of cytosolic phospholipase A 2 α (cPLA 2 α) in inflammatory PGE 2 production in the brain. We wondered if cPLA 2 α functions in inflammation to produce arachidonic acid or to modulate levels of COX-2 or mPGES-1. We investigated these questions in the brains of wildtype and mice deficient in cPLA 2 α (cPLA 2 α -/-) following systemic administration of lipopolysaccharide (LPS). cPLA 2 α -/-mice had significantly less brain COX-2 mRNA and protein expression in response to LPS than wildtype mice. The reduction in COX-2 was most apparent in the cells of the cerebral blood vessels and the leptomeninges. The brain PGE 2 concentration of untreated cPLA 2 α -/-mice was equal to their wildtype littermates.
The inflammatory process is important in the propagation of both acute and chronic neurological injuries such as stroke, Alzheimer disease, and multiple sclerosis (10, 30, 44) .
Inflammatory stimuli generated by cells within the brain and circulating molecules can alter the expression of inflammatory proteins within the brain. The enzyme cyclooxygenase-2 (COX-2) is among the earliest and best characterized of these molecules. Furthermore, inhibition of COX-2 activity appears to be neuroprotective in a variety of animal models of neurological disease (19, 25) .
The COX enzymes convert arachidonic acid to PGH 2 , the common precursor of all prostaglandins and thromboxanes. While there are two COX isoforms, the COX-2 enzyme has been characterized as the inducible form that mediates inflammatory prostanoid generation (36) .
O'Banion demonstrated that COX-2 is induced by IL-1β in cultured glial cells, and studies have demonstrated in vivo induction of COX-2 following inflammatory stimuli (28, 38) . PGE 2 is an important mediator of inflammation in the brain, and PGE 2 levels correlate directly with levels of inflammation in a model of stroke (9) . Three distinct PGE 2 synthase (PGES) enzymes convert PGH 2 into PGE 2 : a glutathione-dependent cytosolic form (cPGES) and two membrane-associated PGES forms (mPGES-1 and -2). Analogous to COXs, PGESs appear to have different cellular distributions and expression patterns (45, 47) . Lipopolysaccharide (LPS) triggers the release of pro-inflammatory cytokines, which induce both COX-2 and mPGES-1 in an identical set of vascular endothelial cells of the central nervous system (CNS) (29, 51) . The coordinated actions of these enzymes produce high levels of PGE 2 within the brains and cerebral spinal fluid of rodents (11, 21) . Studies with COX-2, and mPGES-1 knockout mice have proved that increases in brain PGE 2 and the febrile response are dependent Induction of COX-2 in cPLA 2 α-Deficient Mouse Brain 4 upon COX-2 and mPGES-1 expression (26, 27) . Direct cerebral injection of IL-1β increased levels of PGE 2 , COX-2 and mPGES-1 in mouse brain tissue (31) .
It is believed that phospholipases A 2 (PLA 2 s) are the major source of the arachidonic acid that is required for PGE 2 and other prostanoid synthesis. The PLA 2 s comprise a large enzyme superfamily that produces free arachidonic acid by hydrolyzing the fatty acid at the sn-2 position of membrane glycerophospholipids (reviewed in (8) ). The PLA 2 family includes secretory, small molecular weight PLA 2 s (sPLA 2 s), calcium-independent PLA 2 s (iPLA 2 s), and the intracellular 85-kDa cytosolic PLA 2 (cPLA 2 α). It has been postulated that cPLA 2 α is required for the generation of central arachidonic acid following LPS exposure because cPLA 2 α preferentially liberates arachidonic acid and is subject to diverse mechanisms of regulation (7, 17, 51) . In addition, peritoneal macrophages derived from cPLA 2 α deficient (cPLA 2 α -/-) mice are unable to generate any PGE 2 in response to LPS (3) and cytokine treatment of bone marrow derived mast cells harvested from cPLA 2 α -/-mice fail to induce COX-2 mRNA or protein (15) .
The roles of the PLA 2 s in the coordinated regulation of COX and prostaglandin (PG) production within the CNS are largely unexplored (8 (20) . Unless otherwise specified, mice were injected intraperitoneally with 40 mg/kg LPS or an equivalent volume of pyrogen free saline, 16 ml/kg, using a 27-gauge needle.
Northern blot analysis. Brains were rapidly removed from PBS-perfused mice, frozen in liquid nitrogen and stored at -80˚C until use. Total RNA was extracted using the guanidine isothiocyanate-cesium chloride method (6) . RNA blots were hybridized with [α- Competitive RT-PCR analysis. Competitive RT-PCR was performed to determine amounts of COX-2 mRNA. The protocol was adopted from a previously published study (37) .
A deleted DNA construct was generated using the endogenous COX-2 transcript, but was missing an internal 132-bp fragment. An amplified COX-2 deletion product (mutCOX-2) of 430 bp was constructed and subcloned in plasmid Bluescript. RNA for mutCOX-2 was synthesized with T3 RNA polymerase (Promega) and used for subsequent reverse transcriptioncoupled PCR. Total RNA of mouse brain (1 µg) was reverse-transcribed simultaneously with known amounts of mutCOX-2 RNA and then co-amplified with the same set of primers. The relative amount of each PCR product was measured with densitometry (NIH Image) of ethidium bromide-stained agarose gels. In Fig. 4B the logarithm of the ratio of the optical densities of COX-2 to mutCOX-2 is plotted as a function of the logarithm of the amount of mutCOX-2. The best-fit line was determined by linear regression. When the value of the vertical axis is zero, the amount of competitor equals the amount of native COX-2 mRNA.
In situ hybridization. Digoxigenin-11-UTP (DIG-11-UTP) (Boehringer-Mannheim, Germany)-labeled RNA probes were prepared from 1 µg of BamHI (for antisense RNA probe)-or EcoRI (for sense RNA probe)-linearized murine COX-2 cDNA using 2 µg/µl T3 or T7 RNA polymerase (Promega). The RNA probe was hydrolyzed in alkaline solution (56 mM NaHCO 3 , 84 mM Na 2 CO 3 , 7 mM dithiothreitol, and 3 mM EDTA) at 60˚C for 10 min and ethanol precipitated. RNA concentrations were estimated by comparison to the DIG-labeled control RNA (Boehringer) using an alkaline phosphatase-conjugated antibody (Boehringer). µl of 5-bromo-4-chloro-3-indolyl-phosphate in 4 ml of buffer) at room temperature. Color development was checked and the reaction was terminated by immersing the slides in 10 mM
Tris-HCl, pH 7.5, 1 mM EDTA. The slides were mounted and examined by light microscope.
Western blot analysis. After sacrifice mouse brains were rapidly removed and a single hemisphere from each mouse was homogenized by 20 strokes of a tight-fitting Dounce homogenizer at 4°C in buffer containing protease inhibitors. The crude homogenate was centrifuged at 10,000 x g for 20 min at 4°C, and protein concentration was determined by a modified Bradford assay (BioRad). Proteins were separated on 10-12% acrylamide gels using SDS-PAGE and transferred to PVDF membranes (Immobilon; Millipore, Billerica MA).
Immunofluorescence. Three mice of each genotype were treated with saline or 40 mg/kg
LPS and sacrificed at 6 h. Brains were perfusion fixed, as described above, and 5 µm coronal sections were cut and thaw-mounted on glass slides, rinsed briefly in PBS, and incubated with Two mice were analyzed for each condition, and a minimum of three representative images from each mouse were measured. Applicable results are displayed as means ± SEM, with P < 0.05 considered significant.
RESULTS

Northern blot analysis
Based on previous cell culture experiments, we postulated that cPLA 2 α could effect induced COX-2 expression (15) . To evaluate the effects of systemic LPS injection on COX-2 mRNA expression in the cPLA 2 α +/+ and cPLA 2 α -/-mice, total RNA was extracted from brain, heart and lung tissue and examined by Northern blot analysis. Fig. 1 shows that COX-2 mRNA is scarcely detectable in saline-treated tissues from both cPLA 2 α +/+ and cPLA 2 α -/-mice. LPS injection markedly increased COX-2 mRNA expression in the mouse brains and lungs. Notably, the LPS-induced upregulation of COX-2 mRNA, corrected relative to 18S intensity, was much less in the brain of cPLA 2 α -/-mice (64%, n = 7, P < .01).
In contrast, COX-1 mRNA was constitutively expressed at equivalent levels in the brains of wildtype and cPLA 2 α -/-mice. Treatment of the cPLA 2 α -/-mice with LPS resulted in approximately two-fold reduction in brain COX-1 mRNA when compared to saline-treated mice (n = 3, P < 0.025).
The band for cPLA 2 α in the wildtype mouse tissues shows the expected size for cPLA 2 α of 2.8 kbp, as has been reported previously (7) . In the saline-treated cPLA 2 α +/+ mice, cPLA 2 α mRNA was detected in the lung. After LPS injection, cPLA 2 α mRNA was increased in the brain, heart, and lung. The increase in levels of brain mRNA is consistent with the finding that seizure activity in rats also induces both COX-2 and cPLA 2 α. (48) . As expected, cPLA 2 α mRNA was not seen in the tissues of the cPLA 2 α -/-mice. These results demonstrate that induced COX-2 mRNA depends significantly upon cPLA 2 α.
In order to determine the time of peak levels of COX-2 mRNA in the brain following LPS injection in our model, we harvested total brain RNA at various times. The upregulation of COX-2 reached a maximum between 3-6 h after LPS injection, and then decreased to basal levels at 12 h (data not shown). A small but reproducible second phase of increase in COX-2 mRNA levels occurred at 24 h following the LPS injection. We conducted subsequent experiments at the 6 h time point to ensure high levels of COX-2.
Levels of COX-2 and mPGES-1 mRNA and protein have been demonstrated to be coordinately upregulated in the vasculature of the rat brain following LPS injection (51) . We inquired if mPGES-1 regulation was also abnormal in the cPLA 2 α -/-mouse. Northern hybridization with a probe specific for murine mPGES-1 revealed four transcripts, as has been demonstrated in murine peritoneal macrophages ( Fig. 2 )(49). mPGES-1 was not detected in the saline-treated brains of either genotype (Fig. 2B) . LPS treatment strongly induced mPGES-1 in both the cPLA 2 α +/+ and -/-mice. The mPGES-1 mRNA in the brains of cPLA 2 α -/-mice exhibited a tendency toward increased levels (1.4-fold of wildtype, P = NS, n = 6, Fig. 2B ). This is in contrast to the decreased brain levels of COX-2 mRNA in the cPLA 2 α -/-mouse following LPS treatment ( Fig. 2A ) and suggests that cPLA 2 α-dependent inflammatory gene regulation is specific.
Competitive PCR analysis
In order to more precisely determine the magnitude of LPS-induced upregulation of COX-2 message in cPLA 2 α +/+ and cPLA 2 α -/-mouse brains, we used a highly accurate and specific competitive PCR technique (37) . Fig. 3A shows representative ethidium bromide-stained gels of competitive PCR for COX-2 induced in brain of cPLA 2 α +/+ and cPLA 2 α -/-mice after LPS injection. A higher amount of competitor (mutCOX-2) is needed to compete with the COX-2 products in the cPLA 2 α +/+ brain. Following LPS injection, the cPLA 2 α +/+ brains had 2.3-fold more COX-2 mRNA than did the cPLA 2 α -/-mice (cPLA 2 α +/+ mice, 177 ± 11 pg/µg of total RNA, n = 4; cPLA 2 α -/-mice, 76 ± 7 pg/µg of total RNA, n = 3, P < .05) (Fig. 3C) . By this analysis, the LPS-induced brain COX-2 mRNA of the cPLA 2 α -/-is only 43% of normal, and this compares favorably to the Northern analysis (Fig. 1) .
Localization of COX-2 mRNA in brain after LPS injection
We suspected that COX-2 would be induced at specific sites within the brain and performed in situ RNA hybridization 6 h following LPS injection to define the expression sites. (Fig. 4E) . In contrast, the intensity of the signal was much less in the corresponding regions of the cPLA 2 α -/-brain (Fig. 4G) . We performed densitometric analysis and found that COX-2 mRNA in these regions for cPLA 2 α -/-mice was approximately Fig. 4E ). These results demonstrate that cPLA 2 α-dependent differences in COX-2 mRNA levels are most pronounced in the meninges and within blood vessels following LPS injection. (Fig. 5A ). The levels of cPLA 2 α were not altered 6 h following the treatment with LPS (Fig. 5A) . We determined that mPGES-1 protein was expressed equally in the saline-treated wildtype and cPLA 2 α -/-brains ( Fig.   5C ) Interestingly, 6 h following LPS, there was no significant increase in the mPGES-1 protein levels in the brains of either genotype (Fig. 5C ). In contrast to these findings, COX-2 expression in the brains of the saline-treated cPLA 2 α -/-mice was only 0.31-fold of that of the wildtype mice (P = 0.04) (Fig. B) . Following 6 h of LPS treatment, COX-2 protein was significantly increased in the brains of both cPLA 2 α +/+ and -/-mice. The levels of COX-2 protein 6 hrs following LPS treatment were significantly less (0.72-fold, P = 0.03) in the cPLA 2 α -/-as compared to the LPStreated wildtype mice.
COX
We then used immunofluorescence microscopy to compare the expression of COX-2 protein in specific cells of the brains of cPLA 2 +/+ and cPLA 2 α -/-mice. As expected, COX-2 immunoreactivity was rarely detected after saline injection in either genotype (Figs. 6A-C). In cPLA 2 α +/+ mice, COX-2 immunoreactivity was enhanced 6 h following LPS injection in cells of parenchymal, mid-size blood vessels (Fig. 6D ), blood vessels penetrating cerebral cortex (Figs. 6E), and large blood vessels of the subarachnoid space (Fig. 6G ). COX-2 was present in the leptomeninges and the luminal surface of parenchymal blood vessels. As shown by DAPIstaining of nuclei, COX-2 immunoreactivity appears specifically around the nuclear envelope. COX-2, and mPGES-1. We assessed the functional significance of reduced COX-2 induction and the absence of cPLA 2 α in the cPLA 2 α -/-mouse by measuring the levels of PGE 2 in the whole brains (Fig. 7) . Saline-injected mice of both genotypes had comparable brain levels of PGE 2 (7.7 ± 1.6 ng/g vs. 6.8 ± 0.12 ng/g, P = NS). LPS-induced brain PGE 2 was significantly less in the cPLA 2 α -/-mice as compared to their wildtype littermates (3.6-fold and 6.4-fold respectively, P < .05). We note that while basal PGE 2 was equivalent in both genotypes, the reduced PGE 2 response to LPS correlated very closely with the reduction in induced COX-2 mRNA. It is possible that cPLA 2 α has regulatory effects upon other eicosanoid synthetic enzymes, such as PGD synthases. We have focused on PGE 2 metabolism in this study because of the well-described effects of LPS and other inflammatory agents upon PGE 2 synthesis (21, 50).
DISCUSSION
While basal PGD 2 levels in the brain are higher than those of PGE 2 , LPS treatment amplifies PGE 2 synthesis to a greater extent than PGD 2 (50).
We limited our examination of the PGES enzymes to mPGES-1. While both mPGES-2 and cPGES synthesize PGE 2 , they have been characterized as constitutive enzymes (32, 47) .
Biochemical analysis has demonstrated enzymatic coupling of COX-2 activity to mPGES-1 (33) . We used a high systemic dose of LPS (40 mg/kg) and examined its acute effects upon the cycloxygenase-mPGES-1 axis. This is a well-described model in which both COX-2 and mPGES-1 are induced in vascular endothelial cells (51) . We found that COX-2 mRNA levels peak between 3 and 6 h. Other investigators used similar doses of LPS and found that mPGES-1 RNA responses also peak within this time period (49) . Other PLA 2 s or mechanisms may be the source of arachidonate for PGE 2 synthesis in cPLA 2 α -/-brain as basal PGE 2 concentrations are normal and PGE 2 significantly increases following LPS injection (Fig. 7) . A model of inflammatory pain in which central COX-2 and PGE 2 levels increase dramatically without an increase in central PLA 2 activity supports this hypothesis (41) . Furthermore, selective overexpression of COX-2 in neurons dramatically increases basal CNS PGE 2 levels, indicating that basal arachidonic acid levels are sufficient to produce large increases in PGE 2 (50).
It is not surprising that other forms of PLA 2 or PLA 2 -independent mechanisms are responsible for generating metabolically active arachidonate in the brain. The cPLA 2 α content of rodent brains is low. In rat brain, iPLA 2 activity is at least ten-fold greater than sPLA 2 activity, and cPLA 2 α activity is even less than that of sPLA 2 s (52). In wildtype mice, the cPLA 2 α enzymatic activity of whole brain homogenate was below our ability to detect it using published assays (data not shown) (52) . Other laboratories have also been unable to detect differences in total or specific PLA 2 activities between cPLA 2 α +/+ and -/-mice (4). Rosenberger and colleagues performed a detailed analysis of brain lipid metabolism in the cPLA 2 α -/-mouse and found an increased turnover of arachidonic acid, but no difference in free arachidonic acid concentrations (39) . They also concluded that other sources of arachidonic acid function in the absence of cPLA 2 α (39). Further, it is possible that chronic changes or redundancy of PLA 2 activities in the brains of the cPLA 2 α -/-mouse compensate for cPLA 2 α deficiency. Bosetti and Weerasinghe analyzed in vitro PLA 2 activities of brain homogenate and did not find compensation (4). Our findings may also be strain dependent. Group IIA sPLA2 is a major source of PLA 2 activity in rat brain (52) , but because of a naturally occurring missense mutation, neither C57BL/6J nor Sv129 mouse strains express Group IIA PLA 2 (23) . Further studies with application of specific inhibitors and with cPLA 2 α -/-of different strains should answer these questions.
Our Northern analysis did not reveal differences in basal COX-2 RNA levels, but
Western analysis showed that constitutive COX-2 protein levels were less in the cPLA 2 α -/-brain.
Bosetti and Weerasinghe found that constitutive levels of both COX-2 protein and RNA are reduced in the cPLA 2 α -/-mice (4). It is likely that the more sensitive PCR-based method of those authors detected smaller differences in basal COX-2 RNA. The basal levels of brain PGE 2 in both genotypes were the same in our study, suggesting that small differences in basal COX-2 levels have little impact on unstimulated PGE 2 synthesis. In contrast to COX-2, the mRNA response of mPGES-1 in the cPLA 2 α -/-mice remains intact. In macrophages, mPGES-1 induction is completely dependent upon NF-IL6 and is essential for the PGE 2 response to high-dose LPS (49) . The transcriptional responses of COX-2 and mPGES-1 to inflammatory agents share many features. However, in orbital fibroblasts, the increase in mPGES-1 is a purely inductive process, while levels of COX-2 mRNA are partially dependent upon mRNA stabilization (16) (43) . Finally, products of cPLA 2 α activity, such as PGE 2 , may stabilize COX-2 mRNA (13) . Following injection of IL-1β, however, COX-2 inhibition does not effect COX-2 levels, but does prevent increases in mPGES-1 (31) . We postulate that the cytokine response to LPS induces both COX-response. This is an attractive hypothesis because cPLA 2 α has a preference for phosphatidylcholine-containing phospholipids that are the precursors of PAF (7).
In the future, experiments with specific PLA 2 inhibitors will help determine the mechanisms of cPLA 2 α-dependent COX-2 regulation. There is also a need to further dissect the cPLA 2 α signaling cascade within the CNS and determine the importance of cPLA 2 α in other models of neuroinflammation using both in vivo and cell culture techniques. The availability of mice deficient in other forms of PLA 2 , such as group V or iPLA 2 , will further this work (2, 42) .
Investigation of such knockouts can provide new insights into the production of inflammatory eicosanoids.
The coordinated regulation of COX-2 by cPLA 2 α has important implications for potential therapies. Inhibition and gene knockout of cPLA 2 α have already demonstrated profound improvement in neurologic outcomes of mice following inflammatory, oxidative, and immunologic injuries (3, 22, 24, 46) . It remains to be determined if the benefit of eliminating cPLA 2 α activity in the CNS goes beyond downregulation of the COX-2 response. In the lung, cPLA 2 α propagates injury by COX-2-independent mechanisms of injury propagation (34, 35) . If such effects are also found in the CNS, a specific cPLA 2 α inhibitor may provide benefits beyond those found in traditional non-steroidal or selective COX-2 inhibition. 
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